CD109 Molekülinformation
Molecule Name
DNA polymerase alpha subunit
Molekülalias
CD109,CPAMD7,r150,p180,CPAMD7
Drug Development Progress
Anzahl der klinischen Arzneimittel3
Anzahl der inverkehr gebrachten Arzneimittel2
Höchste Forschungs- und EntwicklungsphaseApproved
Target-Alias
P180，N Syndrome (Mental Retardation， Malformations， Chromosome Breakage)，NSX，VEODS，Polymerase (DNA Directed)， Alpha，POLA1，Polymerase (DNA-Directed)， Alpha (70kD)，DNA Polymerase Alpha 1， Catalytic Subunit，POLA，EC:2.7.7.7，EC 2.7.7.7，DNA Polymerase Alpha Catalytic Subunit，DNA Polymerase Alpha Catalytic Subunit P180，Polymerase (DNA) Alpha 1， Catalytic Subunit，DNA Polymerase I，Polymerase (DNA Directed)， Alpha 1， Catalytic Subunit
Molekülhintergrund
CD109 is a glycosyl phosphatidylinositol (GPI)-linked glycoprotein that localizes to the surface of platelets, activated T-cells, and endothelial cells. CD109 is expressed in many malignant tumors, including various squamous cell carcinomas and adenocarcinomas, and plays a role as a multifunctional coreceptor.CD109 reportedly associates with transforming growth factor (TGF)-β receptors and negatively regulates TGF-β signaling in keratinocytes. Additionally, CD109 is potentially related to signal transducer and activator of transcription-3 signaling and aberrant cell proliferation.
CD109 Produktliste
You Have Viewed 0 Of 0 Results
Klinische Arzneimittelinformation
| Englischer Name | Forschungscode | Forschungsphase | Firma | Indikationen | Klinische Studie |
|---|---|---|---|---|---|
| Clofarabine (Boyen) | BY-101 | Phase 3 Clinical | Boyen Therapeutics Inc | Leukemia, Myeloid, Acute | Details |
| Alkasar-18 | NOAC; Alkasar-18; N4-octadecyl-ara-C | Phase 1 Clinical | University of Zurich | Cerebral Hemorrhage; Neoplasms; Atrial Fibrillation | Details |
| Sapacitabine | CS-682; CYC-682 | Phase 1 Clinical | Daiichi Sankyo Co Ltd | Leukemia; Myelodysplastic Syndromes; Breast Neoplasms; Leukemia, Myeloid, Acute; Lymphoma, T-Cell, Cutaneous; Carcinoma, Non-Small-Cell Lung | Details |
Inverkehr gebrachte Arzneimittelinformation
| Englischer Name | Forschungscode | Forschungsphase | Firma | Frühestes Markenname | Frühestes Genehmigungsland | Früheste Indikation | Früheste Genehmigungsgesellschaft | Früheste Genehmigungsdatum | Indikationen | Klinische Studie |
|---|---|---|---|---|---|---|---|---|---|---|
| Clofarabine | CAFdA; JC0707; GZ-393590; SAR-393590; 2-Cl-2-F-araA | Approved | Genzyme Corp | Clolar, Evoltra, Ivozall, Clofarex | United States | Precursor Cell Lymphoblastic Leukemia-Lymphoma | Genzyme Corp | 2004-12-28 | Neoplasms; Angioimmunoblastic T-cell Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell; Waldenstrom Macroglobulinemia; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Leukemia, Myeloid, Acute; Lymphoma; Lymphoproliferative Disorders; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Histiocytosis, Langerhans-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Multiple Myeloma; Leukemia; Lymphoma, Large B-Cell, Diffuse; Leukemia, Myelomonocytic, Chronic; Myelodysplastic Syndromes; Leukemia, Lymphoid; Intestinal Neoplasms; Lymphoma, T-Cell, Peripheral; Lymphoma, B-Cell, Marginal Zone; Lymphoma, B-Cell; Hematologic Neoplasms; Leukemia, Myeloid; Leukemia, Myelogenous, Chronic; Solid tumours | Details |
| Nelarabine | 506U; 506-U78; GW-506U; GW-506U78; GI-262250X; NSC-686673 | Approved | Novartis Pharma Ag, Glaxosmithkline Plc | Arranon, ArranonG, Atriance | United States | Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | Sandoz | 2005-10-28 | Sezary Syndrome; Mycosis Fungoides; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, T-Cell; Angioimmunoblastic T-cell Lymphoma; Lymphoma, Large-Cell, Anaplastic; Lymphoma, T-Cell, Cutaneous; Waldenstrom Macroglobulinemia; Lymphoma, T-Cell; Lymphoma, Non-Hodgkin; Lymphoma; Leukemia; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Follicular; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Multiple Myeloma; Leukemia-Lymphoma, Adult T-Cell; Myeloproliferative Disorders; Myelodysplastic Syndromes; Plasmacytoma; Lymphoma, B-Cell, Marginal Zone | Details |